Respiratory morbidity in preterm infants predicted by natriuretic peptide (MR-proANP) and endothelin-1 (CT-proET-1).
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
received:
15
05
2020
accepted:
11
03
2021
revised:
09
03
2021
pubmed:
8
5
2021
medline:
18
6
2022
entrez:
7
5
2021
Statut:
ppublish
Résumé
Bronchopulmonary dysplasia (BPD) is a major complication in preterm infants <32 weeks. We aimed to assess whether plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP) and C-terminal pro-endothelin-1 (CT-proET-1) predict respiratory morbidity. This was a prospective, two-center, observational cohort study. MR-proANP and CT-proET-1 were measured at day 7 (±2) of life. Associations with duration of supplemental oxygen and the composite outcome of moderate or severe BPD or death (BPD/death) were investigated. Two hundred and twenty-nine infants <32 weeks were included (median gestational age [GA] 29.6 weeks [interquartile range 29.0-30.7], median birth weight 1150 g [IQR 840-1410]). MR-proANP and CT-proET-1 were associated with the duration of supplemental oxygen in univariable analysis (both p < 0.001) but not after adjusting for co-factors. Infants with BPD/death showed higher plasma levels of MR-proANP (623.50 pmol/L [IQR 458.50-881.38] vs. 308.35 pmol/L [IQR 216.72-538.10]; p < 0.001) and CT-proET-1 (255.40 pmol/L [IQR 202.60-311.15] vs. 198.30 pmol/L [IQR 154.70-297.95]; p = 0.015) compared to infants without BPD/death. Levels of both biomarkers were significantly associated with BPD/death in univariable models but not after adjusting for co-factors. MR-proANP and CT-proET-1 are associated with the duration of supplemental oxygen and the composite outcome BPD/death, but their prognostic value does not complement that of clinical risk factors. Plasma levels of MR-proANP and CT-proET-1, measured on day 7 of life (±2 days) are associated in univariable analyses with duration of supplemental oxygen and the combined outcome of BPD or death in VLGA infants. Associations between both biomarkers and respiratory morbidity do not persist in multivariable models, in particular when gestational age is included. MR-proANP and CT-proET-1 have limited additional value to predict respiratory morbidity in VLGA infants compared to clinical parameters.
Sections du résumé
BACKGROUND
Bronchopulmonary dysplasia (BPD) is a major complication in preterm infants <32 weeks. We aimed to assess whether plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP) and C-terminal pro-endothelin-1 (CT-proET-1) predict respiratory morbidity.
METHODS
This was a prospective, two-center, observational cohort study. MR-proANP and CT-proET-1 were measured at day 7 (±2) of life. Associations with duration of supplemental oxygen and the composite outcome of moderate or severe BPD or death (BPD/death) were investigated.
RESULTS
Two hundred and twenty-nine infants <32 weeks were included (median gestational age [GA] 29.6 weeks [interquartile range 29.0-30.7], median birth weight 1150 g [IQR 840-1410]). MR-proANP and CT-proET-1 were associated with the duration of supplemental oxygen in univariable analysis (both p < 0.001) but not after adjusting for co-factors. Infants with BPD/death showed higher plasma levels of MR-proANP (623.50 pmol/L [IQR 458.50-881.38] vs. 308.35 pmol/L [IQR 216.72-538.10]; p < 0.001) and CT-proET-1 (255.40 pmol/L [IQR 202.60-311.15] vs. 198.30 pmol/L [IQR 154.70-297.95]; p = 0.015) compared to infants without BPD/death. Levels of both biomarkers were significantly associated with BPD/death in univariable models but not after adjusting for co-factors.
CONCLUSIONS
MR-proANP and CT-proET-1 are associated with the duration of supplemental oxygen and the composite outcome BPD/death, but their prognostic value does not complement that of clinical risk factors.
IMPACT
Plasma levels of MR-proANP and CT-proET-1, measured on day 7 of life (±2 days) are associated in univariable analyses with duration of supplemental oxygen and the combined outcome of BPD or death in VLGA infants. Associations between both biomarkers and respiratory morbidity do not persist in multivariable models, in particular when gestational age is included. MR-proANP and CT-proET-1 have limited additional value to predict respiratory morbidity in VLGA infants compared to clinical parameters.
Identifiants
pubmed: 33958715
doi: 10.1038/s41390-021-01493-8
pii: 10.1038/s41390-021-01493-8
pmc: PMC8100356
doi:
Substances chimiques
Biomarkers
0
C-terminal proendothelin-1
0
Endothelin-1
0
Natriuretic Peptides
0
Peptide Fragments
0
Vasodilator Agents
0
Atrial Natriuretic Factor
85637-73-6
Oxygen
S88TT14065
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1478-1484Informations de copyright
© 2021. The Author(s).
Références
Stoll, B. J. et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 126, 443–456 (2010).
doi: 10.1542/peds.2009-2959
Stoll, B. J. et al. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 314, 1039–1051 (2015).
doi: 10.1001/jama.2015.10244
Horbar, J. D. et al. Variation in performance of neonatal intensive care units in the United States. JAMA Pediatr. 171, e164396 (2017).
doi: 10.1001/jamapediatrics.2016.4396
Bhandari, A. & Bhandari, V. Pitfalls, problems, and progress in bronchopulmonary dysplasia. Pediatrics 123, 1562–1573 (2009).
doi: 10.1542/peds.2008-1962
Doyle, L. W. & Victorian Infant Collaborative Study Group. Respiratory function at age 8-9 years in extremely low birthweight/very preterm children born in Victoria in 1991-1992. Pediatr. Pulmonol. 41, 570–576 (2006).
doi: 10.1002/ppul.20412
Anderson, P. J. & Doyle, L. W. Neurodevelopmental outcome of bronchopulmonary dysplasia. Semin Perinatol. 30, 227–232 (2006).
doi: 10.1053/j.semperi.2006.05.010
van Katwyk, S. et al. Lifetime patient outcomes and healthcare utilization for Bronchopulmonary dysplasia (BPD) and extreme preterm infants: a microsimulation study. BMC Pediatr. 20, 136 (2020).
doi: 10.1186/s12887-020-02037-5
Kair, L. R., Leonard, D. T. & Anderson, J. M. Bronchopulmonary dysplasia. Pediatr. Rev. 33, 255–263 (2012). quiz 263–264.
doi: 10.1542/pir.33.6.255
Onland, W. et al. Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study. BMC Pediatr. 13, 207 (2013).
doi: 10.1186/1471-2431-13-207
Lal, C. V. & Ambalavanan, N. Biomarkers, early diagnosis, and clinical predictors of bronchopulmonary dysplasia. Clin. Perinatol. 42, 739–754 (2015).
doi: 10.1016/j.clp.2015.08.004
Sellmer, A. et al. N-terminal pro-B type natriuretic peptide as a marker of bronchopulmonary dysplasia or death in very preterm neonates: a cohort study. PLoS ONE 10, e0140079 (2015).
doi: 10.1371/journal.pone.0140079
Joseph, L. et al. N-terminal pro-B-type natriuretic peptide as a marker of bronchopulmonary dysplasia in premature infants. Am. J. Perinatol. 27, 381–386 (2010).
doi: 10.1055/s-0029-1243312
Song, W., Wang, H. & Wu, Q. Atrial natriuretic peptide in cardiovascular biology and disease (NPPA). Gene 569, 1–6 (2015).
doi: 10.1016/j.gene.2015.06.029
Koller, K. J. & Goeddel, D. V. Molecular biology of the natriuretic peptides and their receptors. Circulation 86, 1081–1088 (1992).
doi: 10.1161/01.CIR.86.4.1081
Wang, T. J. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350, 655–663 (2004).
doi: 10.1056/NEJMoa031994
Khimji, A. K. & Rockey, D. C. Endothelin–biology and disease. Cell Signal. 22, 1615–1625 (2010).
doi: 10.1016/j.cellsig.2010.05.002
Baumann, P. et al. Plasma proendothelin-1 as an early marker of bronchopulmonary dysplasia. Neonatology 108, 293–296 (2015).
doi: 10.1159/000438979
Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723–1729 (2001).
doi: 10.1164/ajrccm.163.7.2011060
Walsh, M. C. et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics 114, 1305–1311 (2004).
doi: 10.1542/peds.2004-0204
Laughon, M. M. et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am. J. Respir. Crit. Care Med. 183, 1715–1722 (2011).
doi: 10.1164/rccm.201101-0055OC
Papile, L. A. et al. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J. Pediatr. 92, 529–534 (1978).
doi: 10.1016/S0022-3476(78)80282-0
Papassotiriou, J. et al. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin. Chem. 52, 1144–1151 (2006).
doi: 10.1373/clinchem.2005.065581
Morgenthaler, N. G. et al. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin. Chem. 50, 234–236 (2004).
doi: 10.1373/clinchem.2003.021204
Chenevier-Gobeaux, C. et al. Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP. Clin. Chem. 56, 1708–1717 (2010).
doi: 10.1373/clinchem.2010.145417
Gegenhuber, A. et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin. Chem. 52, 827–831 (2006).
doi: 10.1373/clinchem.2005.065441
van Hateren, K. J. et al. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events. Clin. Chem. 58, 293–297 (2012).
doi: 10.1373/clinchem.2011.166348
Konig, K. et al. Association of BNP, NTproBNP, and early postnatal pulmonary hypertension in very preterm infants. Pediatr. Pulmonol. 51, 820–824 (2016).
doi: 10.1002/ppul.23391
Avitabile, C. M. et al. Accuracy of brain natriuretic peptide for diagnosing pulmonary hypertension in severe bronchopulmonary dysplasia. Neonatology 116, 147–153 (2019).
Xiong, T. et al. Natriuretic peptides in bronchopulmonary dysplasia: a systematic review. J. Perinatol. 40, 607–615 (2020).
doi: 10.1038/s41372-019-0588-2
Dasgupta, S. et al. NTproBNP as a surrogate biomarker for early screening of pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. J. Perinatol. 38, 1252–1257 (2018).
doi: 10.1038/s41372-018-0164-1
Khan, S. et al. Role of NT-proBNP in the prediction of moderate to severe bronchopulmonary dysplasia in preterm infants. Pediatr. Pulmonol. 55, 376–382 (2020).
doi: 10.1002/ppul.24610
Barton, M. & Yanagisawa, M. Endothelin: 20 years from discovery to therapy. Can. J. Physiol. Pharmacol. 86, 485–498 (2008).
doi: 10.1139/Y08-059
Kambas, K. et al. Endothelin-1 signaling promotes fibrosis in vitro in a bronchopulmonary dysplasia model by activating the extrinsic coagulation cascade. J. Immunol. 186, 6568–6575 (2011).
doi: 10.4049/jimmunol.1003756
El Sayed, M. et al. Endothelin-1 and L-arginine in preterm infants with respiratory distress. Am. J. Perinatol. 28, 129–136 (2011).
doi: 10.1055/s-0030-1263295
Niu, J. O. et al. Early increase in endothelin-1 in tracheal aspirates of preterm infants: correlation with bronchopulmonary dysplasia. J. Pediatr. 132, 965–970 (1998).
doi: 10.1016/S0022-3476(98)70392-0
El Shemi, M. S. et al. Endothelin 1 as a predictor marker for bronchopulmonary dysplasia in preterm neonates with respiratory distress syndrome. J. Neonatal Perinat. Med. 10, 79–83 (2017).
doi: 10.3233/NPM-1653
Shah, P. S. et al. Neonatal outcomes of very low birth weight and very preterm neonates: an international comparison. J. Pediatr. 177, 144–152 e6 (2016).
doi: 10.1016/j.jpeds.2016.04.083